PMID- 16387830
OWN - NLM
STAT- MEDLINE
DCOM- 20060814
LR  - 20181113
IS  - 1468-201X (Electronic)
IS  - 1355-6037 (Print)
IS  - 1355-6037 (Linking)
VI  - 92
IP  - 8
DP  - 2006 Aug
TI  - Impact of chronic oral anticoagulation on management and outcomes of patients 
      with acute myocardial infarction: data from the RICO survey.
PG  - 1077-83
AB  - OBJECTIVE: To determine the prevalence of chronic oral anticoagulant drug 
      treatment (COA) among patients with acute myocardial infarction (AMI) and its 
      impact on management and outcome. METHODS: All patients with ST segment elevation 
      AMI on the RICO (a French regional survey for AMI) database were included in this 
      analysis. COA was defined as continuous use >or= 48 hours before AMI. RESULTS: 
      Among the 2112 patients with ST elevation myocardial infarction (STEMI), 93 (4%) 
      patients were receiving COA. These patients were older and more likely to have a 
      history of hypertension, diabetes and prior myocardial infarction than patients 
      without COA. In addition, fewer patients who received COA underwent reperfusion 
      therapy or received an antiplatelet agent (aspirin/thienopyridines). Moreover, 
      patients receiving COA experienced a higher incidence of in-hospital major 
      adverse events (death, recurrent myocardial infarction or major bleeding, p = 
      0.005). Multivariate analysis showed that only ejection fraction, current smoking 
      and multiple vessel disease, but not COA, were independent predictive factors for 
      major adverse events. In contrast, COA was an independent predictive factor for 
      heart failure when adjusted for age, diabetes, creatinine clearance, reperfusion, 
      heparin and glycoprotein IIb/IIIa inhibitors (odds ratio 2.06, CI 95% 1.23 to 
      3.43, p = 0.005). CONCLUSION: In this population based registry, patients with 
      STEMI with prior use of COA constituted a fairly large group (4%) with an overall 
      higher baseline risk profile than that of patients without COA. Fewer in the COA 
      group received reperfusion therapy or aggressive antithrombotic treatment and 
      they experienced more adverse in-hospital outcomes. Thus, further studies are 
      warranted to develop specific management strategies for this high risk group.
FAU - Oudot, A
AU  - Oudot A
AD  - Service de Cardiologie, CHU Bocage, Dijon, France.
FAU - Steg, P G
AU  - Steg PG
FAU - Danchin, N
AU  - Danchin N
FAU - Dentan, G
AU  - Dentan G
FAU - Zeller, M
AU  - Zeller M
FAU - Sicard, P
AU  - Sicard P
FAU - Buffet, P
AU  - Buffet P
FAU - Laurent, Y
AU  - Laurent Y
FAU - Janin-Manificat, L
AU  - Janin-Manificat L
FAU - L'Huillier, I
AU  - L'Huillier I
FAU - Beer, J C
AU  - Beer JC
FAU - Makki, H
AU  - Makki H
FAU - Morel, P
AU  - Morel P
FAU - Cottin, Y
AU  - Cottin Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20051230
PL  - England
TA  - Heart
JT  - Heart (British Cardiac Society)
JID - 9602087
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
SB  - IM
CIN - Heart. 2006 Aug;92(8):1011-2. PMID: 16844847
MH  - Administration, Oral
MH  - Aged
MH  - Anticoagulants/administration & dosage/*adverse effects
MH  - Drug Interactions
MH  - Female
MH  - Fibrinolytic Agents/*therapeutic use
MH  - France/epidemiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Myocardial Infarction/*drug therapy/epidemiology
MH  - Myocardial Reperfusion/statistics & numerical data
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Prevalence
MH  - Prognosis
MH  - Recurrence
MH  - Risk Factors
PMC - PMC1861111
EDAT- 2006/01/03 09:00
MHDA- 2006/08/15 09:00
PMCR- 2009/08/01
CRDT- 2006/01/03 09:00
PHST- 2006/01/03 09:00 [pubmed]
PHST- 2006/08/15 09:00 [medline]
PHST- 2006/01/03 09:00 [entrez]
PHST- 2009/08/01 00:00 [pmc-release]
AID - hrt.2005.074070 [pii]
AID - ht74070 [pii]
AID - 10.1136/hrt.2005.074070 [doi]
PST - ppublish
SO  - Heart. 2006 Aug;92(8):1077-83. doi: 10.1136/hrt.2005.074070. Epub 2005 Dec 30.